Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PT-217 by Phanes Therapeutics for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to...
PT-217 by Phanes Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
PT-217 by Phanes Therapeutics for Prostate Cancer: Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
PT-217 by Phanes Therapeutics for Neuroendocrine Cancer: Likelihood of Approval
PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Neuroendocrine Cancer. According to GlobalData, Phase...